Literature DB >> 6163193

beta 2-Microglobulin in clinical medicine.

F A Karlsson, L Wibell, P E Evrin.   

Abstract

The production of beta 2-microglobulin in normal subjects is quite constant, about 0.13 mg/h . kg. The catabolism almost exclusively through renal elimination. The protein readily passes the glomerular membrane; subsequently more than 99.9% of the filtered beta 2-microglobulin is reabsorbed and degraded in the proximal tubules, only about 5 micrograms/h of the protein appearing in the final urine. Proximal tubular dysfunction leads to an increased urinary concentration. The serum level of beta 2-microglobulin is determined by the glomerular filtration rate and the rate of synthesis. Increased production, with raised serum levels, is sometimes observed in malignancy--mainly at an advanced state, in conditions with neoplastic proliferation of lymphoid B-cells or in inflammatory disorders connected with an activation of the lymphopoetic system. In body fluids, other than plasma and urine, the content of beta 2-microglobulin seems to often reflect a local production. In this review a presentation of the current status and usefulness of beta 2-microglobulin measurements in clinical medicine is included.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6163193

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest Suppl        ISSN: 0085-591X


  25 in total

1.  Serological lymphocytic activity and patient-reported outcomes in Sjögren's syndrome.

Authors:  Maike Jülich; Anna-Maria Kanne; Bettina Sehnert; Stephan Budweiser; Reinhard E Voll; Florian Kollert
Journal:  Clin Rheumatol       Date:  2018-06-01       Impact factor: 2.980

2.  Urine proteomic profiling of pediatric nephrotic syndrome.

Authors:  Mona Khurana; Avram Z Traum; Manuel Aivado; Meghan P Wells; Manuel Guerrero; Franck Grall; Towia A Libermann; Asher D Schachter
Journal:  Pediatr Nephrol       Date:  2006-06-30       Impact factor: 3.714

3.  Circulating Beta-2 Microglobulin and Risk of Cancer: The Atherosclerosis Risk in Communities Study (ARIC).

Authors:  Anna E Prizment; Amy M Linabery; Pamela L Lutsey; Elizabeth Selvin; Heather H Nelson; Aaron R Folsom; Timothy R Church; Charles G Drake; Elizabeth A Platz; Corinne Joshu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02-05       Impact factor: 4.254

Review 4.  beta 2-Microglobulin amyloidosis. A systemic amyloid disease affecting primarily synovium and bone in long-term dialysis patients.

Authors:  C P Maury
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

5.  Nontraumatic rhabdomyolysis during diabetic ketoacidosis.

Authors:  J Møller-Petersen; P T Andersen; N Hjørne; J Ditzel
Journal:  Diabetologia       Date:  1986-04       Impact factor: 10.122

Review 6.  Dialysis arthropathy, amyloidosis and beta-2 microglobulin.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1987-04       Impact factor: 3.714

7.  Serum beta 2 microglobulin in psoriasis and psoriatic patients.

Authors:  L Pagano; A Venier; L Teofili; R Piscitelli; S Storti; C De Simone; F Larussa; R Marra
Journal:  Klin Wochenschr       Date:  1987-04-01

8.  Beta 2-microglobulin in haematological malignancies.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-28

9.  Urinary cadmium and lead concentrations and their relation to blood pressure in a population with low exposure.

Authors:  J Staessen; C J Bulpitt; H Roels; A Bernard; R Fagard; J V Joossens; R Lauwerys; P Lijnen; A Amery
Journal:  Br J Ind Med       Date:  1984-05

10.  Serum beta 2-microglobulin in systemic sclerosis.

Authors:  L Pagano; S Paoletti; G Afa; R Marra; A Garcovich; B Bizzi
Journal:  Clin Rheumatol       Date:  1985-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.